Medicus Pharma Ltd. functions as a biotechnology company in the clinical development stage, with a core mission to accelerate the creation of innovative medical treatments. Its primary subsidiary, SkinJect Inc., is at the forefront of developing a non-surgical therapy for basal cell carcinoma. This novel approach involves a unique dissolvable microneedle patch, which is designed to administer chemotherapeutic agents directly to the affected tumor cells.